<DOC>
	<DOCNO>NCT00404352</DOCNO>
	<brief_summary>The study 24 month randomize , double-blind , Placebo-controlled , multi-center clinical trial optional 12 month open label extension . The primary objective study evaluate effect fetal bovine serum [ FBS ] -free/human serum albumin [ HSA ] -free formulation Interferon [ IFN ] beta-1a ( RNF ) 44 microgram ( three time weekly weekly ) versus placebo time conversion McDonald multiple sclerosis ( MS ) criterion ( 2005 ) subject first clinical demyelinate event high risk convert MS . The main secondary objective study evaluate effect RNF 44 microgram ( three time weekly weekly ) versus placebo `` Time conversion clinically definite MS ( CDMS ) '' subject first clinical demyelinate event high risk convert MS. At end 24 month double-blind core REFLEX trial , subject convert CDMS decide receive open-label ( OL ) treatment enrol open-label , 12 month extension period evaluate effect RNF 44 mcg three time weekly treatment time conversion McDonald MS time conversion CDMS .</brief_summary>
	<brief_title>REbif FLEXible Dosing Early Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Single , first clinical event suggestive MS within 60 day prior study Day 1 , day randomization ( clock start 24 hour onset ) . The event must new neurological abnormality present least 24 hour , either mono polysymptomatic , paresthesia , vegetative cerebral dysfunction At least two clinically silent lesion T2weighted MRI scan , size least 3 millimeter ( mm ) , least one ovoid periventricular infratentorial EDSS 0 5.0 least one time point screen period start treatment 18 50 year old , inclusive Willing follow study procedure Written inform consent If female , subject must : neither pregnant breastfeeding attempt conceive use highly effective method contraception . A highly effective method contraception define result low failure rate ( [ i.e . ] less 1 percent [ % ] per year ) use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence vasectomise partner Diagnosis MS ( per McDonald criterion 2005 ) Any disease could better explain subject 's sign symptoms Complete transverse myelitis bilateral optic neuritis Subject use use approve MS diseasemodifying drug ( DMD ) Any investigational drug undergone experimental procedure within 12 week prior study Day 1 Oral systemic corticosteroid adrenocorticotropic hormone ( ACTH ) within 30 day prior study Day 1 Total bilirubin great 2.5 time upper limit normal ( ULN ) Subject total aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) alkaline phosphatase ( ALP ) great 2.5 time ULN Inadequate bone marrow reserve , define total white blood cell count le 3.0 x 109 per liter ( /L ) , platelet count le 75 x 109/L , hemoglobin le 100 gram per liter ( g/L ) Current autoimmune disease Major medical psychiatric illness ( include history current severe depressive disorder and/or suicidal ideation ) opinion investigator create undue risk subject could affect compliance study protocol History seizure adequately control treatment Cardiac disease , angina , congestive heart failure arrhythmia Known allergy IFNbeta excipient ( ) study medication Any condition could interfere MRI evaluation ; Known allergy gadoliniumdiethylene triamine pentaacetic acid ( DTPA ) Previously participate study Participated clinical trial within past 6 month Any immunomodulatory immunosuppressive therapy time prior enrollment , include , limited , follow product : IFN , glatiramer acetate ( Copolymer I ) , cyclophosphamide , cyclosporine , methotrexate , linomide , azathioprine , mitoxantrone , teriflunomide , laquinimod , cladribine , total lymphoid irradiation , antilymphocyte monoclonal antibody treatment ( e.g . natalizumab , alemtuzumab/Campath , anticluster differentiation 4 [ CD4 ] ) , intravenous , immunoglobulin ( Igs ) , cytokine anticytokine therapy Any experimental MS treatment prior trial entry , include , limited , statin ( give prevent MS ) pentoxyfylline History alcohol drug abuse Intolerance contraindication paracetamol ( acetaminophen ) ibuprofen Inability administer subcutaneous injection either self caregiver Moderate severe renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Rebif New Formulation</keyword>
	<keyword>Clinical Isolated Syndrome</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>